OMERS Administration Corp’s Gain Therapeutics GANX Stock Holding History

OMERS Administration Corp’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-37,300	Closed	-$120K	–	1128
2025 Q4	$120K	Buy	+37,300	New	+$99.5K	﹤0.01%	958

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

OMERS Administration Corp's GANX Position: Q1 2026 in Review

OMERS Administration Corp sold out of Gain Therapeutics (GANX) in Q1 2026, closing a stake of 37,300 shares — an estimated $120K sold.

OMERS Administration Corp first reported a position in GANX in Q4 2025 and held it in 1 quarter. The position peaked at $120K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

OMERS Administration Corp reported no remaining Gain Therapeutics position as of Q1 2026 after selling out during the quarter.
OMERS Administration Corp sold 37,300 Gain Therapeutics shares in Q1 2026, an estimated $120K.
OMERS Administration Corp first reported a position in Gain Therapeutics in Q4 2025 and held it in 1 quarter.
OMERS Administration Corp's Gain Therapeutics position peaked at $120K in Q4 2025.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.